AI Insight
This randomized phase 3 trial compared high-dose chemotherapy followed by autologous stem-cell transplantation (HCT-ASCT) versus non-myeloablative consolidation in patients with primary central nervous system lymphoma (PCNSL) who completed induction treatment. The study, representing the largest randomized trial in untreated PCNSL, demonstrated that HCT-ASCT significantly improved both progression-free survival and overall survival compared to non-myeloablative consolidation. These results establish HCT-ASCT as the preferred consolidation strategy for fit patients with PCNSL.
Why it matters
This trial provides high-quality evidence that changes the standard of care for PCNSL treatment, offering patients a consolidation approach that meaningfully extends survival. The findings will directly inform clinical decision-making and treatment protocols for this rare and aggressive brain cancer in patients healthy enough to tolerate intensive therapy.
Understand the Science
In the largest randomised trial in untreated PCNSL to date, HCT–ASCT significantly improved progression-free and overall survival compared with non-myeloablative consolidation in patients who had completed induction treatment, establishing it as the preferred consolidation strategy in fit patients.